Brief: Gain Therapeutics Begins Its Gt-02287 Phase 1b Extension Study In People With Parkinson’s Disease
18/09/2025 12:55
Sept 18 (Reuters) - Gain Therapeutics Inc GANX.O: GAIN THERAPEUTICS BEGINS ITS GT-02287 PHASE 1B EXTENSION STUDY IN PEOPLE WITH PARKINSON’S DISEASE Source text: ID:nGNX1X265c Further company coverage: GANX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gain Therapeutics
See all newsU.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Gain Therapeutics climbs on narrower-than-expected quarterly loss
Gain Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall